Informations sur le produit
- (3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-[[[6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dimethoxybenzoyl)-2-O-methyl-beta-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-beta-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-oxacyclooctadeca-3,5,9,13,15-pentaen-2-one
- 3''',5'''-Di-O-methyltiacumicin B
Applications 3’’’,5’’’-Dideshydroxy-3’’’,5’’’-dimethoxy Fidaxomicin is a derivative of Fidaxomicin (F335400), a nonabsorbed macrocyclic antibiotic, and is also the first antimicrobial to be approved by the FDA for the treatment of Clostridium difficile infection (CDI) in 20 years.
References Babakhani, F., et al.: Clin. Infect. Dis., 55, S162 (2012); Venugopal, A., et al.: Clin. Infect. Dis., 54, 568 (2012)